uPA/uPAR系统在肿瘤中作用的研究进展  

Role of uPA/uPAR system in tumors

作　　者：尚润泽 戴斌[1] 王德盛[1] 

机构地区：[1]中国人民解放军第四军医大学西京医院肝胆外科,陕西省西安市710032

出　　处：《世界华人消化杂志》2014年第9期1235-1240,共6页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81030010;陕西省科技研究发展计划基金资助项目No.2012FS2-09-1~~

摘　　要：尿激酶型纤溶酶原激活物(urokinase type plasminogen activator,uPA)是纤溶酶原的重要激活物之一,其特异性受体为纤溶酶原激活物受体(urokinase type plasminogen activator receptor,uPAR).大量研究表明,uPA/uPAR系统对纤溶酶原活性起调控作用,参与多种与基细胞外基质降解、重塑相关的病理生理过程.肿瘤组织中,在uPA/uPAR系统的作用下将纤溶酶原激活为纤溶酶,促进基底膜和细胞外基质内相关成分的降解,为肿瘤的侵袭、转移提供有利微环境.此外,uPA/uPAR系统对于肿瘤的增殖及肿瘤血管形成也具有调控作用.本文就uPA/uPAR系统在肿瘤中的作用及其临床意义做一综述.Urokinase type plasminogen activator （uPA） is a major activator of plasminogen, and uPA re- ceptor is the specific receptor of uPA. The uPA/ uPAR system regulates plasminogen activity, which participates in degradation and remod- eling of the extracellular matrix （ECM）, and is involved in many pathophysiological processes. In neoplasms, the activation of plasminogen into plasmin caused by the uPA/uPAR system induces the degradation of components in the basement membrane as well as in the ECM, which provides a favorable microenvironment for tumor invasion and metastasis. In addition, the uPA/uPAR system regulates tumor prolif- eration and angiogenesis. In this review, we will discuss the role of the uPA/uPAR system in tu- mors and its potential clinical implications.

关 键 词：尿激酶型纤溶酶原激活物 纤溶酶原激活物受体系统 肿瘤 尿激酶型纤溶酶原激活物 纤溶酶原 

分 类 号：R730.2[医药卫生—肿瘤]